DRAVP ID  DRAVPe02317

Peptide Name   EBOV-6

Sequence  DWTKNIKDKIDKIIHDFVDKTLPDQGC

Sequence Length  26

UniProt ID  No entry found

Taxon ID  None

Source  Cholesterol-conjugated synthetic peptide

Validation   Experimentally Validated

Gene Name/ID  Not Available

GenBank  Not Available

Amino Acid position  Not Available

Domain Accession ID  Not Available

Nucleotide sequence ID  Not Available

Molecular Type  Not Available

Chromosomal Position  Not Available

Target Organism  EBOV

Assay  Not Available

Activity 

• [Ref:31473342]EBOV:EC50=1.90 plusminus 0.39 microM, 3.67 plusminus 0.89 microM, 5.44 plusminus 0.85 microM; EBOV EC90 = 9.84 microM, 15.33 microM, 25.75 microM.EBOV-GP EC50 = 1.82 plusminus 0.55 microM; EBOV-GP EC90 = 29.46 microM.ma-EBOV EC50 = 7.95 plusminus 28.30 microM; ma-EBOV EC90 = 211 microM.GP => GlycoProtein; ma => Mouse-Adapted

Hemolytic Activity  No hemolysis information or data found in the reference(s) presented in this entry

Cytotoxicity 

• [Ref:31473342]EBOV-6 show cytotoxicity (CC50) at greater than 30 microM.EBOV-5 show cytotoxicity (CC50) at >= 25 microM (when tested for EBOV-GP).EBOV-5 show cytotoxicity (CC50) at >= 47.4 microM (whe

Binding Target  Glycoprotein.

Mechanism  EBOV-6 works against the Ebola virus by targeting the fusion process required for the virus to enter host cells. Specifically, it binds to the C-terminal heptad-repeat (HR2) domain of the Ebola virus glycoprotein GP2. This binding disrupts the formation of the fusion complex, a critical structure that facilitates the merging of the viral and host cell membranes. By interfering with this fusion process, EBOV-6 prevents the virus from entering and infecting the host cells. Consequently, this inhibition leads to a reduction in viral replication and spread, making EBOV-6 a potential antiviral agent against Ebola virus infection

PDB ID  None

Predicted Structure Download 

Linear/Cyclic  Cyclic

N-terminal Modification  cholesterylation

C-terminal Modification  PEG12

Other Modification  In the peptide sequence, the cysteine residue at position 27 is modified with a PEG4-cholesterol (PEG4-Chol) moiety.)

Stereochemistry  L

Literature 1

Title   Cholesterol-conjugated stapled peptides inhibit Ebola and Marburg viruses in vitro and in vivo

Pubmed ID   31473342

Reference   Antiviral Res. 2019;171:104592. 

Author   Pessi A, Bixler SL, Soloveva V, et al

DOI   10.1016/j.antiviral.2019.104592